Associations of DMARDs with post-acute sequelae of COVID-19 in patients with systemic autoimmune rheumatic diseases: a prospective study.

Rathnam K VenkatXiaosong WangNaomi J PatelYumeko KawanoAbigail SchiffEmily N KowalskiClaire E CookKathleen M M VanniGrace QianKatarina J BadeAlene SaavedraShruthi SrivatsanZachary K WilliamsZachary S WallaceJeffrey A Sparks

Published in: Rheumatology (Oxford, England) (2023)

CD20i users had significantly higher odds of PASC and fewer symptom-free days over the 28 days following COVID-19 diagnosis compared with csDMARD users. Further research is needed to investigate whether PASC risk in CD20i users may be due to prolonged infection or other immune mechanisms. The association of IL-12/23i, IL-17Ai, and IL-23i and PASC calls for additional study.

Keyphrases

coronavirus disease
sars cov
drug induced
liver failure
multiple sclerosis
artificial intelligence
respiratory syndrome coronavirus
respiratory failure
systemic lupus erythematosus
rheumatoid arthritis
hepatitis b virus
deep learning
disease activity